U.S., Sept. 18 -- ClinicalTrials.gov registry received information related to the study (NCT07824271) titled 'Safety and Pharmacokinetics of ALZ-507 in Healthy Elderly Adults' on Aug. 31.
Brief Summary: Researchers are testing an investigational medicine called ALZ-507 in healthy adults between 50 and 75 years of age.
The purpose of this study is to learn:
Assess if oral ALZ-507 is safe What side effects may occur How the body absorbs ALZ-507 Whether food affects how ALZ-507 is absorbed How much ALZ-507 reaches the blood, cerebrospinal fluid, and urine
Participants will receive either ALZ-507 or a placebo. Some participants will receive a single dose, while others will receive daily doses for two weeks. Researchers will monitor particip...